Atr Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ATR (Ataxia-Telangiectasia and Rad3 Related) is a member of the PI3/PI4-related family of protein kinases and functions as a critical regulator of the DNA damage response. Unlike ATM, which responds primarily to double-strand breaks, ATR is activated by replication stress and single-stranded DNA lesions. ATR plays essential roles in maintaining genomic stability, regulating cell cycle checkpoints, and coordinating DNA repair processes. Germline mutations in ATR cause Seckel syndrome, a disorder characterized by microcephaly and growth retardation.
The ATR protein contains several key domains:
- FHA Domain: Forkhead-associated domain for protein-protein interactions
- BRCT Domains: Breast cancer C-terminal domains for DNA binding
- PI3K Domain: Kinase catalytic domain for phosphorylation activity
- ATRIP Binding Domain: Interaction site for ATRIP, the essential ATR partner
- Replication Stress Response: ATR senses stalled replication forks
- SSDNA Accumulation Detection: Recognizes RPA-coated single-stranded DNA
- Chk1 Activation: Phosphorylates Chk1 to propagate the checkpoint signal
- Replication Fork Stabilization: Prevents fork collapse and collapse
- S-Phase Checkpoint: Prevents replication origin firing under stress
- G2/M Checkpoint: Blocks mitotic entry with DNA damage
- Intra-S Checkpoint: Inhibits late origin firing
- Centrosome Maturation: Regulates centrosome duplication
- Homologous Recombination: Promotes HR repair pathway choice
- Nucleotide Excision Repair: Facilitates NER activity
- Base Excision Repair: Modulates BER efficiency
- Non-Homologous End Joining: Suppresses error-prone NHEJ
- ATR Mutations: Hypomorphic mutations cause ATLD
- Neurological Features: Cerebellar ataxia, oculomotor apraxia
- Cellular Defects: Neuronal sensitivity to DNA damage
- Therapeutic Approaches: Gene therapy, protein replacement
- Germline Mutations: Increased cancer risk
- Seckel Syndrome: Developmental abnormalities
- Therapeutic Vulnerability: ATR inhibitors in cancer
- Alzheimer"s Disease: DNA damage accumulation
- Parkinson"s Disease: Oxidative DNA damage response
- Huntington"s Disease: DNA repair deficits
- VE-822 (VX-970): First-generation ATR inhibitor
- AZD6738 (Ceralasertib): Clinical-stage inhibitor
- M6620 (Berzosertib): Topoisomerase I inhibitor combination
- Synthetic Lethality: With TP53 mutations
- Chemotherapy Sensitization: Enhanced DNA damage
- Radiotherapy Enhancement: Increased tumor cell death
| Partner |
Function |
| ATRIP |
Essential regulatory subunit |
| Chk1 |
Downstream effector kinase |
| RAD9 |
Checkpoint clamp component |
| RPA |
Single-stranded DNA binding |
| BRCA1 |
DNA repair coordination |
| TOPBP1 |
ATR activation |
- ATR-Deficient Mice: Embryonic lethal, replication stress sensitivity
- Conditional Knockouts: Neuron-specific ATR deletion models
- ATLD Mouse Models: Recapitulate neurological phenotype
The study of Atr Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] ATR: The key DNA damage response kinase. Nat Rev Mol Cell Biol. 2019;20(11):687-700. PMID:31637807
[2] ATR signaling in replication stress and cancer. Mol Cell. 2020;79(2):209-220. PMID:32649873
[3] Seckel syndrome and ATR mutations. Hum Mol Genet. 2018;27(R2):R139-R148. PMID:29982647
[4] ATR inhibitors in cancer therapy. Nat Rev Cancer. 2021;21(8):531-546. PMID:34131357
[5] DNA damage response in neurodegeneration. Nat Rev Neurosci. 2022;23(11):649-666. PMID:36123404